Inflammatory bowel diseases (IBD) are chronic conditions of unknown etiology. Current therapy mitigates the severity of acute bouts of mucosal inflammation but an eradication therapy is lacking. Growing incidence of IBD is associated with social development. Epidemiology suggests a relationship between the establishment of the individual gut flora and the risk of developing IBD. Patients show an impaired tolerance towards commensal bacteria of the resident flora. Unrestrained activation of the intestinal immune system against some commensal bacteria appears to be responsible for the characteristic relapsing course of these diseases. Wide-spectrum antibiotic therapy reduces bacterial load and mitigates intestinal inflammation in human IBD and in animal models. Current research aims at the identification of probiotics for bacterial antagonism therapies. Probiotics are living microorganisms which upon ingestion in certain numbers exert health benefits beyond inherent basic nutrition. Colonization with a Lactobacillus reuteri strain can prevent the development of colitis in genetically susceptible mice. Other studies have used a bacterium genetically engineered to secrete the antiinflammatory cytokine IL-10 and demonstrated a therapeutic effect in animal models of colitis. Moreover, some probiotics may naturally exhibit antiinflammatory properties when interacting with the human gut mucosa. Prebiotics such as inulin have also been shown to prevent colonic inflammation in animal models. Preliminary clinical trials with probiotics in IBD are encouraging. Probiotics offer a valuable tool for the prevention and control of inflammatory bowel diseases.
Inflammatory bowel diseases
The term 'Inflammatory Bowel Disease' (IBD) refers primarily to two major disorders, ulcerative colitis and Crohn's disease. Both entities are chronic conditions characterized by recurrent inflammatory lesions involving the gut mucosa. Ulcerative colitis is essentially a disease involving the mucosa only. The rectum is always affected and the disease may spread diffusely from the rectum towards the cecum, but the inflammatory disorder is limited to the large intestine. Crohn's disease is a transmural inflammatory process involving the full thickness of the intestinal wall, from mucosa to serosa, and may affect any point along the gastrointestinal tract. Skip areas of normal intestine are found between areas of inflamed tissue. The diagnosis may be made in children or young adults, and the patients never achieve a definitive cure of the disease. Current therapy mitigates the severity of acute bouts of inflammation but an eradication therapy is lacking. This is mainly due to the fact that the aetiology of the diseases is not known.
Since World War II, the incidence of IBD has increased dramatically, especially in developed countries of the world. Epidemiological data suggest that growing incidence of IBD is associated with social development. Prevalence of IBD in developed societies is now estimated as 512 cases per 100 000 persons by the age of 43 y (Thompson et al, 2000) . Environmental factors related to economic development may play a significant role. For instance, exposure to poor sanitation in infancy decreases the future risk of developing Crohn's disease (Gent et al, 1994) . Likewise, prisoners of the Vietnam War show low risk for Crohn's disease (Delco & Sonnenberg, 1998) . Rural populations are less frequently affected than urban ones. Lack of breastfeeding in infancy, a high sucrose consumption and a high intake of animal fat are associated with an increased risk for IBD (Reif et al, 1997; Corrao et al, 1998) . Lactose consumption shows no effect while fructose intake is associated with decreased risk for IBD (Reif et al, 1997) . Regular consumption of citric fruits and fresh vegetables also shows an association with decreased risk (Reif et al, 1997; Russel et al, 1998) . Introduction of Western foods such as hot dogs, butter and margarine into the diets of Japanese populations increases IBD risk (Epidemiology Group of the Research Committee of Inflammatory Bowel Disease in Japan, 1994; Shoda et al, 1996) . As shown in Table 1 , frequent use of antibiotics for otitis or pharyngitis during childhood has also been identified as a risk factor for developing Crohn's disease (Wurzelmann et al, 1994) .
Interestingly, environmental factors positively related to increased risk of IBD are opposite to the factors that facilitate the transmission of infectious diseases: low hygiene and poor sanitation, rural environment, lack of antibiotic use, consumption of unprocessed foods, etc. In fact, transmission of Crohn's disease or ulcerative colitis has never been documented. This clearly suggests that host factors play an important pathogenetic role. A genetic background of susceptibility is confirmed by the observation that first-degree relatives of IBD patients have a 10-fold increase in the risk of developing IBD (Orholm et al, 1991) .
Current concepts on the pathophysiology of IBD consider the confluence of three interactive cofactors: genetic susceptibility, altered mucosal immunity and environmental challenges, mostly related to the acquisition and establishment of the enteric microflora (Shanahan, 2001) .
Mucosal immunity
Patients with Crohn's disease or ulcerative colitis show an impaired tolerance to antigens present in the intestinal lumen. Data by Brandtzaeg and coworkers showed that counts of IgG producing lymphocytes in histological sections from human intestinal mucosa are consistently increased in patients with Crohn's disease or ulcerative colitis as compared with healthy controls (Brandtzaeg et al, 1989) . This suggests that mucosal immunity in IBD is altered. Normal responses are based on the production of IgA antibodies that perform immunoexclusion of microbes and antigens on the surface of the epithelium. These responses do not induce inflammation or tissue damage. In contrast, antibodies of the IgG class neutralize antigens within the tissue and form IgG-immunocomplexes that activate the complement, triggering a full inflammatory response that may be harmful to the host tissue. Intestinal T-lymphocytes are also hyperreactive in IBD, and data by Pirzer et al showed that local tolerance mechanisms are abrogated in Crohn's disease (Pirzer et al, 1991) . In fact, patients with Crohn's disease or ulcerative colitis show an impaired tolerance towards commensal bacteria of the resident flora (Macpherson et al, 1996) . These findings suggest that commensal bacteria present within the intestinal lumen might induce immuno-inflammatory responses that may damage the intestinal mucosa. Unrestrained activation of the intestinal immune system by the enteric flora would be responsible for the characteristic relapsing course of the diseases.
Bacteria and bowel inflammation
The concept that luminal bacteria are involved in mucosal inflammation is supported by data from different experimental models. Pre-treatment with antibiotics has been shown to mitigate intestinal inflammation in several animal models, including indomethacin-induced lesions (Kent et al, 1969; Yamada et al, 1993) , sodium-dextran sulphate (Okayasu et al, 1990 ) colitis and granulomatous colitis by TNBS, as shown in our laboratory (Videla et al, 1994) . In addition, colitis induced by the transfer of normal CD 4þ =CD45RBhi T lymphocytes to SCID mice can be successfully treated with a mixture of oral non-absorbable antibiotics (Morrisey & Charrier, 1994) . In our study, we found that early antibiotic treatment reduced mucosal lesion scores in TNBS colitis. However, the effect was only observed when the antibiotics were administered topically, ie by enema or by oral route in the case of non-absorbable preparations, but the same antibiotics failed to induce inflammatory remission when administered by parenteral route (Videla et al, 1994) . This finding clearly suggested that a reduction of bacterial counts within the colonic lumen was essential for the induction of an anti-inflammatory effect.
Strong evidence for the role of normal enteric bacteria in intestinal inflammation is also provided by the mitigation of the disease in animals bred in a germ-free environment. For example, HLA-B27 transgenic rats spontaneously develop chronic colitis, but germ-free transgenic rats fail to develop intestinal inflammation (Taurog et al, 1994) . Likewise, IL-2 deficient mice develop inflammatory bowel disease at 10 weeks of age. The disease shares histological similarity with human ulcerative colitis, and appears to be triggered by the intestinal flora since mice kept under germ-free conditions do not develop the disease (Sadlack et al, 1993) . Intestinal inflammation in IL-10 knockout mice is also exacerbated by the presence of normal, non-pathogenic intestinal microflora (Kühn et al, 1993) . These studies are consistent with the 
Immuno-inflammatory responses against specific bacteria
On the other hand, it is well established that the colonic microflora play a crucial role in the development of the intestinal immune system (Woolverton et al, 1992; Umesaki et al, 1993) . Animals kept in germ-free conditions exhibit immature intestinal immunity (Helgeland et al, 1996) . The germ-free state is therefore not suitable for the investigation of pathogenetic mechanisms which may involve immune reactivity. This is the case for haptens such as TNBS (Kunin & Gallily, 1983; Morris et al, 1989) . Intestinal immune responses are likely to play a role in tissue injury in this model, since intravenous administration of TNBS 6 weeks after induction of colitis reactivates colonic lesions (Appleyard & Wallace, 1995). Thus, our approach was to use rats bred in a conventional state, with a fully developed immune system. We prepared rats with a colonic segment that was surgically excluded from faecal transit. The excluded segment allows radical elimination of the indigenous flora and re-colonization with preselected bacterial species. Using this in vivo model, we examined the effects of colonization of the excluded segment with different bacterial species on the inflammatory response to luminal instillation of TNBS (García-Lafuente et al, 1997). Our experiments showed that several bacterial species of the common rat microflora, including anaerobes, penetrate within the colonic wall of rats exposed to TNBS. Bacterial invasion of the submucosa was observed as soon as 24 h after intracolonic administration of TNBS. Such invasion was not observed in control rats not exposed to TNBS. Interestingly, we found that instillation of TNBS into a colonic segment without bacterial colonization did not cause significant inflammatory lesions. In rats without bacterial colonization, TNBS did not induce mucosal release of inflammatory mediators or leucocyte accumulation into the bowel wall. In contrast, rats colonized with aerobes showed mucosal lesions and inflammatory changes after intracolonic instillation of TNBS. However, the full response to TNBS was only observed in rats colonized with anaerobes from the common rat flora. The release of PGE2, TXB2 and LTB4 after TNBS challenge was significantly higher in rats with mixed flora than in rats with aerobes only. Likewise, involvement of the submucosa was significantly greater in the presence of anaerobes than with only aerobes. Thus, we were able to demonstrate that anaerobic bacteria present in the colonic flora are mostly responsible for the development of deep colonic lesions and a severe inflammatory response after TNBS instillation. Our data suggested that some anaerobic species are critical to the development of transmural inflammatory lesions. Mucosal invasion by bacteria from the ordinary nonpathogenic flora including some anaerobic species appears to induce transmural inflammation.
Transmural inflammation
We also explored the role of single bacteria species in the induction of transmural inflammation (Mourelle et al, 1998) . Several bacteria strains from different species of the predominant flora were isolated from pathogen-free rats, and prepared as suspensions of living bacteria that were used for inoculation into the colonic wall of normal rats. The effects of bacteria on stimulation of TGFb1 and collagen deposition within the intestinal wall were studied. Interestingly, we found that enteric bacteria differ in their fibrogenic capability and this appears to be linked to the type of the inflammatory response they produce. Lactobacillus, a predominant species of the enteric flora in rats and humans, did not induce noticeable inflammation and resulted in similar changes to the injections of normal saline. Most aerobic bacteria provoked a severe acute inflammatory reaction which was circumscribed to focal areas of abscesses, but stimulation of TGFb1 and local deposition of collagen were negligible. Conversely, the obligate anaerobes tested (Bacteroides fragilis, Bacteroides uniformis and Clostridium ramosum) induced a mild acute granulocyte response but a widely diffuse infiltration of mononuclear cells, involving the serosa in most cases, and associated with accumulation of collagen in the tissue. Thus, our data suggested that some anaerobes that are predominant in the colonic flora share a significant potential to induce diffuse fibrogenic responses when invading the intestinal wall.
Antibiotics in human IBD
In human inflammatory bowel diseases, commensal bacteria living in the gut may also stimulate inflammatory activity of the mucosal lesions. We conducted a randomized 5-day study to investigate whether administration of broad spectrum antibiotics decreases inflammatory activity in patients with chronic ulcerative colitis (Casellas et al, 1998) . Thirty patients admitted to the hospital for active disease were randomly allocated into three treatment groups: the antibiotic group received orally an enteric coated preparation of amoxicillin -clavulanic acid (1 g þ 250 mg, three times daily); the steroid group received oral placebo and i.v. methylprednisolone (40 mg=day); and finally, a combinedtreatment group received both oral amoxicillin -clavulanic acid and i.v. methylprednisolone. After 5 days on treatment, the intrarectal release of IL-8 significantly decreased in patients treated with the antibiotic preparation (antibiotic group and combined treatment group). However, steroid treatment did not induce significant changes in the rectal mucosal release of IL-8 (see Figure 1) . Clinical activity scores decreased in all three groups after 5 days on treatment. Our study demonstrates that short-term treatment with topical broad-spectrum antibiotics rapidly reduces mucosal inflammation in active ulcerative colitis. Wide-spectrum antibiotic therapy reduces bacterial load and mitigates intestinal inflammation in human IBD, suggesting that some species of the human colonic flora may play a detrimental role on the natural course of idiopathic mucosal inflammation.
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Probiotics
Current research aims at the identification of probiotics for bacterial antagonism therapies. Probiotics are living microorganisms which upon ingestion in certain numbers exert health benefits beyond inherent basic nutrition (Guarner & Schaafsma, 1998) . A recent experimental study has shown that colonization with a Lactobacillus reuteri strain can prevent the development of colitis in genetically susceptible mice (Madsen et al, 1999) . Prebiotics such as inulin have also been shown to increase the number of Lactobacilli in faecal samples and prevent colonic inflammation in animal models (see Figure 2 , Videla et al, 2001 ). Other studies have used a bacterium genetically engineered to secrete the antiinflammatory cytokine IL-10 and demonstrated a therapeutic effect in animal models of colitis (Steidler et al, 2000) . Moreover, some probiotics may naturally exhibit antiinflammatory properties when interacting with the human gut mucosa. Recently, the effect of bacteria on TNFa release by intestinal mucosa was investigated in our laboratory (Borruel et al, 2002) . Ileal specimens were obtained at surgery from patients with Crohn's disease and controls undergoing right hemicolectomy for caecal cancer. Mucosal explants from each specimen were cultured for 24 h with either a non-pathogenic strain of Escherichia coli, or different bacteria strains with known probiotic properties. Co-culture of mucosa with bacteria did not modify tissue viability. Interestingly, the release of TNF-a by inflamed Crohn's disease mucosa was significantly reduced by co-culture with Lactobacillus casei DN114001, whereas changes induced by L. crispatus or E. coli were not significant. In addition, co-culture of inflamed intestinal tissue with L.casei reduced the number of CD4 cells, as well as TNF-a expression among intra-epithelial lymphocytes. Our findings suggest that some bacteria are able to interact with immunocompetent cells using the mucosal interface, and can modulate locally the production of proinflammatory cytokines.
Preliminary clinical trials of probiotic therapy in IBD are encouraging (Gionchetti et al, 2000) and, in the near future, probiotics may offer a valuable tool for the prevention and control of inflammatory bowel diseases. Figure 1 Rectal mucosal release of interleukin-8 in patients with active ulcerative colitis prior to and after a 5 day treatment course with either i.v. methyl-prednisolone and oral placebo or oral amoxicyllin -clavulanic acid administered in enteric coated capsules to prevent absorption of the antibiotic in the small bowel (see Casellas et al, 1998) . The release of interleukin-8 significantly decreased in patients treated with the antibiotic preparation. Wide-spectrum antibiotic therapy reduces bacterial load and mitigates intestinal inflammation in human IBD. Figure 2 Colitis induced by DSS in the rat is significantly attenuated by the prebiotic inulin administered orally as a dietary supplement (400 mg=day), as evidenced by lower colonic lesion scores, and lower myeloperoxidase activity in colonic tissue than in control rats not receiving the supplement (see Videla et al, 2001 ).
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